Sahu, Kamal KantCerny, Jan2022-08-232022-08-232020-06-252020-07-08<p>Sahu KK, Cerny J. Managing patients with hematological malignancies during COVID-19 pandemic. Expert Rev Hematol. 2020 Jun 25. doi: 10.1080/17474086.2020.1787147. Epub ahead of print. PMID: 32580592. <a href="https://doi.org/10.1080/17474086.2020.1787147">Link to article on publisher's site</a></p>1747-4094 (Linking)10.1080/17474086.2020.178714732580592https://hdl.handle.net/20.500.14038/27612The outbreak of the coronavirus disease 2019 (COVID‐19) has posed an unprecedented challenge to the health care communities across the globe. As of June 17th, 2020, a total of 8,339,829 confirmed COVID-19 cases with 448,420 deaths have been reported [2]. Different parts of the world are seeing different levels of COVID-19 activity with regards to the infection rate, susceptible population, and mortality rate. The COVID-19 pandemic is a rapidly evolving emergency and is a subject of regular debate and advanced research. Patients with hematological disorders and solid malignancies have special needs and oncologists are facing a compound challenge.en-USThis is an Accepted Manuscript of an article published in Expert Review of Hematology, posted after 12-month embargo as allowed by the publisher's author self-archiving policy at https://authorservices.taylorandfrancis.com/sharing-your-work/#.COVID-19CancerHematologyPandemicHealth Services AdministrationHematologyHemic and Lymphatic DiseasesInfectious DiseaseNeoplasmsOncologyVirus DiseasesAccepted Manuscripthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1064&amp;context=covid19&amp;unstamped=1https://escholarship.umassmed.edu/covid19/6218421075covid19/62